Ultrasound contrast developer ImaRx Pharmaceutical is rampingup its manufacturing capacity and personnel lineup as it preparesfor the commercial launches of several new products.The Tucson, AZ, company last month tapped Henry "Pete"Manspeaker
Ultrasound contrast developer ImaRx Pharmaceutical is rampingup its manufacturing capacity and personnel lineup as it preparesfor the commercial launches of several new products.
The Tucson, AZ, company last month tapped Henry "Pete"Manspeaker as vice president and director of clinical operationsof its newly formed clinical research department. Manspeaker wasmost recently director of clinical research at Alliance Pharmaceuticalof San Diego.
Manspeaker will work in conjunction with ImaRx Pharmaceutical'sU.S. licensee, Du Pont Merck Pharmaceutical, on the completionof clinical trials related to ImaRx's Aerosomes (MRX-115) microbubble-basedultrasound contrast agent technology (SCAN 12/13/95). Aerosomesis about to begin phase III clinical trials.
Other agents ImaRx is developing include gastrointestinal MRIagent LumenHance; gastrointestinal ultrasound agent SonoRx; TomoRx,a CT agent for the gastrointestinal tract; and MRX-408, a thrombus-specificultrasound contrast agent.
The company also announced that a physical plant expansion, whichwill result in the construction of a new 18,000-square-foot facility,should be finished by late 1997. Following the completion of theproject, the company anticipates that it will double its workforce to 50 employees.
In other personnel moves, ImaRx announced that Thomas Fritz hasbeen promoted from director of operations to vice president andchief operating officer.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.